Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

atment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that new distribution agreements or other commercialization efforts will effectively accelerate InnerCool's patient temperature modulation business, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, that necessary regulatory approvals will be obtained. Actual results may also
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Israel Biomedical Sensors Market - Growth, Trends ... The Israel Biomedical Sensors market is estimated ... 3.73% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged ... development approval process. Thus, innovator companies must understand what will be needed in ... CMO, has been hosting multiple educational panels and seminars for experts to share ...
(Date:8/28/2015)... 2015 Research and Markets ... "Global & USA BioSimilar Market Analysis to 2021" ... awaited US Biosimilar market will be initiated in September ... How will the global market react? Will biosimilars explode ... could save the US economy up to $250 billion ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... Inc. announced today that it has been awarded funding ... pre-clinical research targeting alpha-synuclein, a protein whose clumping is ... NeuroPhage,s first grant from MJFF. "It ... development of our novel therapeutic approach.  This grant will ...
... ARBOR, Mich., Feb. 16, 2012  Adeona Pharmaceuticals, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... of stockholders to change its corporate name to Synthetic ... will start trading under its new name and stock ...
... February 15, 2012 CitiusTech, a leading ... the calendar year 2011 with 59% growth in revenues. ... has recorded over 50% Y-o-Y revenue growth. In 2011, ... healthcare technology. CitiusTech was selected as a finalist at ...
Cached Biology Technology:NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinson's Disease Research 2CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011 2
(Date:8/25/2015)... SALT LAKE CITY and BELLEVUE, ... a global leader in advanced robotic systems, announced today ... first-of-its-kind robotic unmanned ground vehicle (UGV), at the National ... Lake City.  The Guardian S is ... is the culmination of years of research and in-field ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... Scientists have identified a genetic variation in people ... muscle cells respond to the hormone insulin, in a ... The researchers, from Imperial College London and other international ... scientists developing treatments for diabetes. Previous studies have ...
... to restore to normal levels a key protein involved ... have been shown to cause the rare brain disorder ... mental retardation and very early death in human infants. ... mice, that the genetic equivalent to human lissencephaly, also ...
... what you know often comes at the price of learning ... easy for many, but not for those with conditions such ... simple routines. Using brain scans in monkeys, Duke ... monkeys will switch from exploiting a known resource to exploring ...
Cached Biology News:Scientists discover new genetic variation that contributes to diabetes 2Researchers restore missing protein in rare genetic brain disorder 2Researchers restore missing protein in rare genetic brain disorder 3Monkey brains signal the desire to explore 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: